NCT07223125 is a Phase 1 clinical trial of JNJ-89862175 in Advanced-stage Solid Tumors, sponsored by Janssen Research & Development, LLC.

Who is sponsoring NCT07223125?

NCT07223125 is sponsored by Janssen Research & Development, LLC.

What drugs are being tested in NCT07223125?

Interventions in NCT07223125: JNJ-89862175.

What condition does NCT07223125 study?

NCT07223125 studies Advanced-stage Solid Tumors.

Is NCT07223125 still recruiting?

NCT07223125 is currently recruiting now. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT07223125

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors

Recruiting now Phase 1 Last updated 13 April 2026

What this trial tests

Phase 1 trial testing JNJ-89862175 in Advanced-stage Solid Tumors in 360 participants. Currently enrolling.

Timeline

10 October 2025

Primary endpoint
15 December 2026

15 August 2028

Quick facts

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	360
Start date	10 October 2025
Primary completion	15 December 2026
Estimated completion	15 August 2028
Sites	6 locations across France, United States, South Korea

Drugs / interventions tested

JNJ-89862175 — full drug profile →

Conditions studied

Advanced-stage Solid Tumors — all drugs for Advanced-stage Solid Tumors →

Sponsor

Janssen Research & Development, LLC — full company profile →

Who can join

18 and older, any sex, with Advanced-stage Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \[RP2Ds\]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Janssen Research & Development, LLC trials

Trials by the same sponsor.

NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07223125 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07223125.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing